explore -WSS

explore

author：Wikipedia 2025-09-29 05:58:46 - browse：4

Liver illustration — Hyacinth Empinado/STAT

SAN DIEGO — The American Diabetes Association said Sunday that all adults with type 2 diabetes or prediabetes should be screened for nonalcoholic fatty liver disease, an increasingly prevalent condition that can lead to serious liver damage.

There are no approved medications for the disease, but among available diabetes drugs, the ADA singled out GLP-1 treatments as an option doctors could consider, according to recommendations published during the annual ADA conference.

GLP-1 treatments, such as Ozempic and Mounjaro, are a class of drugs that have grown widely popular for their efficacy not only in lowering blood sugar, but also cutting weight. Drugmakers have started to study them in liver disease, and while some trials have shown they may offer some benefits, they haven’t yet been shown to improve harmful liver scarring.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

focus

WSS

Congenital heart disease patients face new threat of heart failure

Editas, Vertex strike deal on CRISPR

Prime Medicine, Myeloid Therapeutics clash over genome

Why sickle cell disease is getting the first CRISPR treatment

Christmas in the PICU brings some surprising joy

SEC charges former device maker CEO with $41 million fraud

hotspot

explore

leisure time

Drug repurposing or repositioning? The language matters

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Activists slam private health insurers over coverage restrictions

David Ricks of Eli Lilly: best biopharma CEO of 2023

New air purifier tech could be key to improving indoor air quality

What PEPFAR has meant on the ground in Ukraine

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Chemotherapy shortages won’t get better under Biden’s latest plan

Medical records are filled with copy

Three trends to watch in biotech in 2024

entertainment

How to keep neuroscience’s past racism from being its future

Hospitals owned by private equity see complications spike 25%

Radiology is caught between AI's potential and concern for patients

Medicare Advantage beneficiaries sue Humana over algorithm use

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Chemotherapy shortages won’t get better under Biden’s latest plan

focus

focus

knowledge

focus